Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7803014 | 0.90 | BDKRB2 (0.73) | BDKRB2 | |
| SCHEMBL4059811 | 0.87 | BDKRB2 (0.76) | BDKRB2 | |
| SCHEMBL7807566 | 0.86 | BDKRB2 (0.68) | BDKRB2 | |
| SCHEMBL4056235 | 0.85 | BDKRB2 (1.00) | BDKRB2 | |
| SCHEMBL4059008 | 0.84 | BDKRB2 (1.00) | BDKRB2 | |
| SCHEMBL4058616 | 0.83 | BDKRB2 (0.65) | BDKRB2 | |
| SCHEMBL7807830 | 0.83 | BDKRB2 (0.68) | BDKRB2 | |
| SCHEMBL5905834 | 0.82 | BDKRB2 (0.64) | BDKRB2 | |
| SCHEMBL7807760 | 0.81 | BDKRB2 (0.65) | BDKRB2 | |
| SCHEMBL4057179 | 0.81 | BDKRB2 (1.00) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491825-B2 | Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | MENARINI RICERCHE S.P.A. (IT) | 2009-02-17 | — | — | US | claimed |
| US-20060205712-A1 | Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | MENARINI RIEERCHE S.P.A. (IT) | 2006-09-14 | — | — | US | claimed |
| EP-1513531-B1 | BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | MENARINI RICERCHE SPA (IT) | 2009-10-21 | — | — | EP | disclosed |
| US-7491825-B2 | Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | MENARINI RICERCHE S.P.A. (IT) | 2009-02-17 | — | — | US | disclosed |
| US-20060205712-A1 | Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | MENARINI RIEERCHE S.P.A. (IT) | 2006-09-14 | — | — | US | disclosed |
| EP-1513531-A1 | BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Menarini Ricerche S.p.A. (IT) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003103671-A1 | BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | MENARINI RICERCHE S.P.A. (IT) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205712-A1 | Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | BDKRB2, BDKRB1, AGTR2 | BDKRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.